The CD123 (I元-R.alpha.).times.CD3 bispecific antibody orĪntigen-binding fragment of claim 6 wherein HC1 comprises SEQ ID (I元-R.alpha.).times.CD3-bispecific binding fragment thereof.ħ. To form a first antigen-binding site that immunospecifically bindsĬD123 (I元-R.alpha.), and the HC2 and the LC2 pair to form a secondĪntigen-binding site that immunospecifically binds CD3, or a CD123 (HC1) b) a second heavy chain (HC2) c) a first light chain (LC1) Īnd d) a second light chain (LC2), wherein the HC1 and the LC1 pair Or antigen-binding fragment comprising: a) a first heavy chain An isolated CD123 (I元-R.alpha.).times.CD3 bispecific antibody The antibody or antigen-binding fragment of any of claims 1 to 4Ħ. SEQ ID NO: 136 and light chain of the antibody comprises the aminoĥ. The antibody or antigen-binding fragment of claim 1, wherein the SEQ ID NO: 120, and the light chain of the antibody comprises theĤ. Heavy chain of the antibody comprises the amino acid sequence of ID NO: 025, and a light chain CDR3 having the amino acid sequenceģ. NO: 024, a light chain CDR2 having the amino acid sequence of SEQ Heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 052,Ī heavy chain CDR3 having the amino acid sequence of SEQ ID NO:Ġ53, a light chain CDR1 having the amino acid sequence of SEQ ID a heavyĬhain CDR1 having the amino acid sequence of SEQ ID NO: 051, a Having the amino acid sequence of SEQ ID NO: 017 or b. The amino acid sequence of SEQ ID NO: 016, and a light chain CDR3 Sequence of SEQ ID NO: 013, a heavy chain CDR3 having the aminoĪcid sequence of SEQ ID NO: 014, a light chain CDR1 having theĪmino acid sequence of SEQ ID NO: 015, a light chain CDR2 having Of SEQ ID NO: 012, a heavy chain CDR2 having the amino acid a heavy chain CDR1 having the amino acid sequence The isolated antibody, or an antigen-binding fragment of claimġ, comprising: a. An isolated antibody, or antigen-binding fragment thereof, thatīinds immunospecifically to CD123 SP2 (IL-3Ra) and CD123 SP1Ģ. (Dresher, PA) Luo Jinquan (Malvern, PA) McDaid Ronan (Eagleville, PA) Pomerantz
Washington, PA) Gaudet Francois (Princeton, The multispecific antibodies against CD123 and CD3 described Treatment with a CD123-specific anti-cancer therapeutic, such as Treated for cancer or to determine whether or not a subject isĪfflicted with CD123-expressing cancer and thus may be amenable to Or stability to determine whether or not a patient should be Treat, or monitor CD123-expressing cancer progression, regression, InĪddition, methods of using the provided antibodies are described.įor example, the provided antibodies may be used to diagnose, Also described are related polynucleotides capable ofĮncoding the provided CD123-specific antibodies or antigen-bindingįragments, cells expressing the provided antibodies orĪntigen-binding fragments, as well as associated vectors andĭetectably labeled antibodies or antigen-binding fragments. Provided herein are antibodies that immunospecifically bind toĬD123. Tam, Alexey Teplyakov, John Wheeler, Sheng-Jiun Wu. Harman, Yingzhe Li, Jinquan Luo, Ronan McDaid, Jennifer F. Invention is credited to Ricardo Attar, Francois Gaudet, Benjamin C. The applicant listed for this patent is Janssen Pharmaceutica NV. This patent application is currently assigned to JANSSEN PHARMACEUTICA NV. patent application number 14/844194 was filed with the patent office on for cd123 binding agents and uses thereof.
CD123 Binding Agents and Uses Thereof Nemeth Jennifer F.